Clinical Trials

Phase 2 Active not recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT05941520 2026-04-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-04-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

200 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06195306 2026-04-13

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Phase 2 Recruiting

66 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00601900 2025-05-23

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

394 enrolled 11 charts

Breast Neoplasms

NCT00005970 2020-08-14

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

3,436 enrolled

Breast Neoplasms

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

19 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00590785 2017-08-25

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

60 enrolled

Breast Neoplasms

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00003418 2013-12-19

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

4,400 enrolled

Breast Neoplasms

NCT00003678 2013-12-19

Tamoxifen in Treating Women With Breast Cancer

20,000 enrolled

Breast Neoplasms

NCT00010140 2013-12-18

Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer

Breast Neoplasms

NCT00002579 2013-11-06

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT00002580 2013-11-06

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00002581 2013-11-06

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00002755 2013-11-06

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

600 enrolled

Breast Neoplasms

NCT00003679 2013-11-06

Combination Chemotherapy in Treating Women With Breast Cancer

350 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

300 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

Phase NA Unknown

100 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00002720 2013-09-20

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

642 enrolled

Breast Neoplasms

NCT00003013 2013-09-17

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

450 enrolled

Breast Neoplasms

NCT00002460 2013-08-07

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Breast Neoplasms

NCT00006030 2013-08-07

Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

2,500 enrolled

Breast Neoplasms

NCT00002582 2013-08-02

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

6,000 enrolled

Breast Neoplasms

NCT00032136 2013-08-02

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

4,400 enrolled

Breast Neoplasms

NCT00002967 2013-06-21

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT00052728 2013-06-19

Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

Breast Neoplasms

NCT00003992 2013-06-03

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

200 enrolled

Breast Neoplasms

NCT00047099 2013-05-30

Combination Chemotherapy in Treating Women With Breast Cancer

446 enrolled

Breast Neoplasms

NCT00005908 2013-03-19

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

30 enrolled 12 charts

Breast Neoplasms

NCT00016276 2013-01-16

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Phase 3 Terminated

396 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms, Cardiotoxicity

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

1,500 enrolled

Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2 Unknown

94 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003016 2009-02-09

Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer

20,000 enrolled

Breast Neoplasms

NCT00033683 2009-02-09

Combination Chemotherapy in Treating Women With Resected Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

Phase 2 Unknown

2,000 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00228930 2008-09-25

Tamoxifen Pharmacogenetics and Clinical Effects

Completed

297 enrolled